Evotec (NASDAQ:EVO) Reaches New 52-Week Low – Here’s Why

Evotec AG (NASDAQ:EVO)’s stock price hit a new 52-week low during trading on Tuesday . The stock traded as low as $1.8950 and last traded at $1.90, with a volume of 8258 shares changing hands. The stock had previously closed at $1.96.

Analyst Upgrades and Downgrades

EVO has been the topic of a number of recent analyst reports. TD Cowen cut shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price objective on the stock. in a research note on Wednesday, July 15th. Wall Street Zen downgraded Evotec from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evotec in a research report on Tuesday, July 21st. HC Wainwright dropped their target price on shares of Evotec from $7.00 to $4.00 and set a “buy” rating for the company in a report on Wednesday, July 15th. Finally, Berenberg Bank downgraded shares of Evotec from a “buy” rating to a “hold” rating in a research note on Thursday, July 16th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Evotec currently has an average rating of “Hold” and a consensus price target of $3.00.

Evotec Stock Down 3.1%

The company has a debt-to-equity ratio of 0.62, a current ratio of 2.33 and a quick ratio of 2.21. The business has a fifty day simple moving average of $2.36 and a 200-day simple moving average of $2.79.

Institutional Investors Weigh In On Evotec

Several hedge funds have recently added to or reduced their stakes in EVO. Apollon Wealth Management LLC bought a new position in shares of Evotec during the first quarter valued at $28,000. Marshall Wace LLP acquired a new stake in shares of Evotec in the fourth quarter valued at about $40,000. SmartHarvest Portfolios LLC acquired a new position in shares of Evotec in the first quarter worth approximately $44,000. BNP Paribas Financial Markets lifted its stake in shares of Evotec by 62.2% in the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock worth $50,000 after acquiring an additional 4,600 shares during the period. Finally, Bank of America Corp DE increased its position in Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after purchasing an additional 9,289 shares during the period. 5.81% of the stock is currently owned by institutional investors and hedge funds.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.